Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43917447" target="_blank" >RIV/00216208:11120/18:43917447 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/18:10384928 RIV/00216208:11150/18:10384928 RIV/00179906:_____/18:10384928 RIV/00064173:_____/18:N0000092 RIV/00064203:_____/18:10384928
Výsledek na webu
<a href="https://doi.org/10.1186/s40425-018-0446-3" target="_blank" >https://doi.org/10.1186/s40425-018-0446-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s40425-018-0446-3" target="_blank" >10.1186/s40425-018-0446-3</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients
Popis výsledku v původním jazyce
A high density of tumor-infiltrating CD8+ T cells and CD20+ B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma (HGSC). However, the potential impact of mature dendritic cells (DCs) in shaping the immune contexture of HGSC, their role in the establishment of T cell-dependent antitumor immunity, and their potential prognostic value for HGSC patients remain unclear. We harnessed immunohistochemical tests and biomolecular analyses to demonstrate that a high density of tumor-infiltrating DC-LAMP+ DCs is robustly associated with an immune contexture characterized by TH1 polarization and cytotoxic activity. We showed that both mature DCs and CD20+ B cells play a critical role in the generation of a clinically-favorable cytotoxic immune response in HGSC microenvironment. In line with this notion, robust tumor infiltration by both DC-LAMP+ DCs and CD20+ B cells was associated with most favorable overall survival in two independent cohorts of chemotherapy-naïve HGSC patients. Our findings suggest that the presence of mature, DC-LAMP+ DCs in the tumor microenvironment may represent a novel, powerful prognostic biomarker for HGSC patients that reflects the activation of clinically-relevant anticancer immunity.
Název v anglickém jazyce
Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients
Popis výsledku anglicky
A high density of tumor-infiltrating CD8+ T cells and CD20+ B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma (HGSC). However, the potential impact of mature dendritic cells (DCs) in shaping the immune contexture of HGSC, their role in the establishment of T cell-dependent antitumor immunity, and their potential prognostic value for HGSC patients remain unclear. We harnessed immunohistochemical tests and biomolecular analyses to demonstrate that a high density of tumor-infiltrating DC-LAMP+ DCs is robustly associated with an immune contexture characterized by TH1 polarization and cytotoxic activity. We showed that both mature DCs and CD20+ B cells play a critical role in the generation of a clinically-favorable cytotoxic immune response in HGSC microenvironment. In line with this notion, robust tumor infiltration by both DC-LAMP+ DCs and CD20+ B cells was associated with most favorable overall survival in two independent cohorts of chemotherapy-naïve HGSC patients. Our findings suggest that the presence of mature, DC-LAMP+ DCs in the tumor microenvironment may represent a novel, powerful prognostic biomarker for HGSC patients that reflects the activation of clinically-relevant anticancer immunity.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal for ImmunoTherapy of Cancer
ISSN
2051-1426
e-ISSN
—
Svazek periodika
6
Číslo periodika v rámci svazku
December
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
13
Strana od-do
"Article 139"
Kód UT WoS článku
000452804900001
EID výsledku v databázi Scopus
2-s2.0-85058319459